Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function.

News | Heart Valve Technology

First Intermediate to Long-term Study of the Harmony Transcatheter Pulmonary Valve System Validates Safety and Efficacy

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

May 19, 2022

First multi-center, randomized controlled study provides the largest long-term evidence for the treatment of heavily calcified femoropopliteal lesions

News | Peripheral Artery Disease (PAD)

Disrupt PAD III Trial Demonstrates Safety and Effectiveness of Intravascular Lithotripsy for Peripheral Artery Calcification

May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...

May 19, 2022

Study evaluates therapy optimization and system management of endovascular pulmonary neuromodulation in ADHF

News | Heart Failure

Cardionomic Announces First Patient Enrolled in STIM-ADHF Study

May 19, 2022 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in ...

May 19, 2022

Findings help identify patients who may not be optimally managed for recurrent stroke prevention

News | Stroke

Continuous Monitoring Detects Four Times More Atrial Fibrillation Incidence Following Stroke than Intermittent Monitoring

May 18, 2022 — Continuous monitoring with an insertable cardiac monitor (ICM) is shown to be more successful in ...

May 18, 2022

Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

News | Pharmaceuticals

Research Shows Potential to Reduce Major Cardiovascular (CV) Events

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

May 17, 2022

Key members of the research collaboration: (from left) Prof Roger Foo (Programme Director, ATTRaCT, and Senior Group Leader, GIS), Dr Karin Conde-Knape (Senior Vice President, Global Drug Discovery, Novo Nordisk), Dr Rasmus Rabøl (Corporate Vice President, Global Translation, Novo Nordisk), Dr Natasha Michaelsen (Principal Scientist, Global Translation, Novo Nordisk), Prof Mark Richards (Director, Cardiovascular Research Institute, NUS, and Deputy Director, National University Heart Centre), Prof Derek Haus

News | Heart Failure

A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and Bioinf ...

May 16, 2022

CRF Meeting Covering Structural Heart Disease Innovations Will Take Place June 8-10

News | TVT

Late-Breaking Science Announced for TVT 2022

May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

May 16, 2022

Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally

News

Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

May 13, 2022

Woon-Hong Yeo has developed a smarter stent. Georgia Tech Photo

News | Stents

Georgia Tech Researchers Develop Wireless Implantable Vascular Monitoring System

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

May 13, 2022

The Neurescue device is an FDA-approved device currently in use for patients with severe bleeding which will now be used in a new study to help increase survival rate for those who experience in-hospital cardiac arrests

News | Sudden Cardiac Arrest

MemorialCare Long Beach Medical Center Only Site in Nation to Offer ARISE-Study – New Experimental Treatment for In-Hospital Cardiac Arrest

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only ...

May 13, 2022

Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists

News | Cardiovascular Business

Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more ...

May 12, 2022

A microscopy picture of muscle cells in a normal heart (left) and muscle cells in a heart of a patient with hypertrophic cardiomyopathy (right). The black areas are single muscle cells. The muscle cells of the hypertrophic cardiomyopathy patient are bigger, and there is more space in between the cells (green), which is filled with scar tissues in the case of patients with hypertrophic cardiomyopathy. The blue indicates where the DNA of the cells can be found. Image courtesy of Anne de Leeuw, copyright Hubre

News | Cardiovascular Clinical Studies

Single Cell RNA Sequencing Uncovers New Mechanisms of Heart Disease

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

May 11, 2022

Back on track after its in-person hiatus, ACC22 stressed industry resilience, and featured practice-changing science and innovations

Feature | ACC | By Melinda Taschetta-Millane

ACC22: Transforming Cardiovascular Care

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

May 11, 2022

Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI

News | STEMI

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

May 10, 2022 — Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 st ...

May 10, 2022

$Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction$

News | Cardiovascular Clinical Studies

FARXIGA Met Primary Endpoint in DELIVER Phase III Trial

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

May 05, 2022